Skip to main content
OpenTrials
Completed

NCT Number: NCT06967129

Evaluation of Daily Disposable Toric Soft Lenses Manufactured With an Alternative Hydration Process

This is a prospective, multi-site, dispensing, randomized, controlled, double-masked, bilateral wear, 2x2 crossover study to evaluate the safety and effectiveness of the test lens.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

James R. Dugue, Optometrist, Mission Viejo, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

  • Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Be between 18 and 39 (inclusive) years of age at the time of screening.
  • By self-report, habitually wear soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 2 days per week during last 30 days.
  • Possess a wearable pair of spectacles that provide correction for distance vision.
  • In both eyes, have astigmatic refractive error suitable for correction with the toric contact lens powers available in this study:
  • Sphere powers (DS) -1.50 through -4.00 (inclusive) in 0.25 steps
  • Cylinder powers (DC) -0.75 and -1.25
  • Axes (°) 170, 180, 10, 80, 90, 100
  • Have best corrected monocular distance visual acuity of 20/30 or better in each eye.

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

  • Be currently pregnant or lactating.
  • Be diabetic.
  • Be currently using any ocular medications or have an ocular infection of any type.
  • By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
  • Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
  • Be currently wearing monovision or multifocal contact lenses.
  • Be currently wearing lenses in an extended wear modality.
  • Have a history of strabismus or amblyopia.
  • Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
  • Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment.
  • Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
  • Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
  • Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, Photorefractive Keratectomy [PRK], Laser-Assisted in Situ Keratomileusis [LASIK], iridotomy, retinal laser photocoagulation, etc.).

Treatment and study plan

Investigational daily disposable, soft, toric lenses manufactured on 4th Generation Technology (4GT) lines with extended mini-stack hydration using propylene glycol (PG) as the hydration solvent.

Device

Test Lens

ACUVUE® Oasys 1-Day for Astigmatism (AO1DfA) soft contact lenses manufactured on 3rd Generation Technology (3GT) legacy lines using isopropyl alcohol (IPA) as the hydration solvent.

Device

Control Lens

Primary outcomes

  1. Distance (4m) Monocular High Luminance High Contrast (HLHC) logMAR Visual Acuity (VA)

    Time frame: At each 1-week follow-up per wear period

    VA will be assessed monocularly under HLHC conditions at a test distance of 4 meters using ETDRS Charts.

  2. Toric Lens Orientation

    Time frame: At baseline per wear period

    Toric lens orientation (scribe mark position relative to 6 o'clock) will be assessed for each eye at 15 minutes after lens insertion. Toric lens orientation will be used to define a binary endpoint, i.e. the percentage of eyes that achieve absolute toric lens rotation ≤ 10°.

  3. Lens Rotational Stability with Blinks

    Time frame: At baseline per wear period

    Rotational stability will be assessed for each eye at least 15 minutes after lens insertion. Lens rotational stability with blinks will be defined as a binary endpoint, the percentage of eyes that achieve rotational stability with blinks ≤ 5°.

  4. Percentage of eyes with Grade 3 or higher SLFs relating to the test lens

    Time frame: Up to 3-week follow-up

    SLFs (Grade 3 or higher) related to study lens wear for the test lens will be assessed for each eye at all study visits (scheduled and unscheduled). SLFs will be evaluated and graded using the FDA Grading scale from 0 to 4, where Grade 0 represents the absence of findings and 1 to 4 representing successively worse findings. The percentage of eyes with Grade 3 or higher SLF will be analyzed and will include corneal infiltrates.

  5. Percentage of eyes with acceptable lens fitting while wearing the test lens

    Time frame: Up to 3-week follow-up

    Acceptable lens fit will be assessed at all study visits (scheduled and unscheduled) for each subject eye and used to define a binary endpoint, i.e. the percentage of eyes that achieve acceptable lens fit while wearing the test lens.

    Lens fit will be deemed unacceptable if any one of the following criteria are met:

    • limbal exposure at primary gaze or with extreme eye movement.
    • edge lift.
    • excessive movement on blink in primary gaze.
    • insufficient movement in all three of the following conditions: primary gaze, up gaze, and push up test.

Secondary outcomes

  1. Subjective Overall Comfort

    Time frame: At each 1-week follow-up per wear period

    Subjective overall Comfort scores will be assessed using the CLUE questionnaire. CLUE™ is a validated, patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, for wearers between 18 to 65 years of age. CLUE™ scores are derived using Item Response Theory (IRT) and follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

  2. Subjective Overall Quality of Vision

    Time frame: At each 1-week follow-up per wear period

    Subjective Overall Quality of Vision scores will be assessed using the CLUE questionnaire. CLUE™ is a validated, patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, for wearers between 18 to 65 years of age. CLUE™ scores are derived using Item Response Theory (IRT) and follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

  3. Subjective Overall Handling

    Time frame: At each 1-week follow-up per wear period

    Subjective Overall Handling scores will be assessed using the CLUE questionnaire. CLUE™ is a validated, patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, for wearers between 18 to 65 years of age. CLUE™ scores are derived using Item Response Theory (IRT) and follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Vision Care, Inc.

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 13, 2025
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.